The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 15, 2012
Filed:
Feb. 04, 2009
Arno G. Steinig, East Northport, NY (US);
Mark J. Mulvihill, East Northport, NY (US);
Jing Wang, Syosset, NY (US);
Douglas S. Werner, Holtsville, NY (US);
Qinghua Weng, West Islip, NY (US);
Heather Coate, San Diego, CA (US);
Xin Chen, Commack, NY (US);
Arno G. Steinig, East Northport, NY (US);
Mark J. Mulvihill, East Northport, NY (US);
Jing Wang, Syosset, NY (US);
Douglas S. Werner, Holtsville, NY (US);
Qinghua Weng, West Islip, NY (US);
Heather Coate, San Diego, CA (US);
Xin Chen, Commack, NY (US);
OSI Pharmaceuticals, LLC, Farmingdale, NY (US);
Abstract
2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.